Theravex® for Burning Mouth Syndrome
NCT: NCT07564843 · COMPLETED
Brief Summary
In this randomized, double-blind, placebo-controlled trial, 116 adults with primary BMS were assigned (1:1) to receive THERAVEX® Total Oral Care Plus or placebo for 8 weeks. Participants rinsed 10 mL for 60 seconds three times daily. The primary outcome was change in burning pain intensity (Numeric Rating Scale, NRS). Secondary outcomes included responder rate (≥2-point NRS reduction), Oral Health Impact Profile-14 (OHIP-14), Xerostomia Inventory, Patient Global Impression of Change (PGIC), and safety assessments.
Frequently Asked Questions
What is Theravex® for Burning Mouth Syndrome?
Theravex® for Burning Mouth Syndrome is a clinical trial registered under NCT07564843. Current status: COMPLETED.
What is the status of NCT07564843?
The current status of NCT07564843 (Theravex® for Burning Mouth Syndrome) is: COMPLETED.
When did Theravex® for Burning Mouth Syndrome start?
Theravex® for Burning Mouth Syndrome started on 2024-10-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.